Literature DB >> 10783792

Estimation of sojourn time in chronic disease screening without data on interval cases.

T H Chen1, H S Kuo, M F Yen, M S Lai, L Tabar, S W Duffy.   

Abstract

Estimation of the sojourn time on the preclinical detectable period in disease screening or transition rates for the natural history of chronic disease usually rely on interval cases (diagnosed between screens). However, to ascertain such cases might be difficult in developing countries due to incomplete registration systems and difficulties in follow-up. To overcome this problem, we propose three Markov models to estimate parameters without using interval cases. A three-state Markov model, a five-state Markov model related to regional lymph node spread, and a five-state Markov model pertaining to tumor size are applied to data on breast cancer screening in female relatives of breast cancer cases in Taiwan. Results based on a three-state Markov model give mean sojourn time (MST) 1.90 (95% CI: 1.18-4.86) years for this high-risk group. Validation of these models on the basis of data on breast cancer screening in the age groups 50-59 and 60-69 years from the Swedish Two-County Trial shows the estimates from a three-state Markov model that does not use interval cases are very close to those from previous Markov models taking interval cancers into account. For the five-state Markov model, a reparameterized procedure using auxiliary information on clinically detected cancers is performed to estimate relevant parameters. A good fit of internal and external validation demonstrates the feasibility of using these models to estimate parameters that have previously required interval cancers. This method can be applied to other screening data in which there are no data on interval cases.

Entities:  

Mesh:

Year:  2000        PMID: 10783792     DOI: 10.1111/j.0006-341x.2000.00167.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  21 in total

1.  MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle Broemeling
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

2.  Simulation Procedure in Periodic Cancer Screening Trials.

Authors:  Dongfeng Wu; Xiaoqin Wu; Ioana Banicescu; Ricolindo L Cariño
Journal:  J Mod Appl Stat Methods       Date:  2005-11

3.  Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence.

Authors:  Nora Pashayan; Paul Pharoah; László Tabár; David E Neal; Richard M Martin; Jenny Donovan; Freddie Hamdy; Stephen W Duffy
Journal:  Cancer Epidemiol       Date:  2010-08-16       Impact factor: 2.984

4.  The continuum of breast cancer care and outcomes in the U.S. Military Health System: an analysis by benefit type and care source.

Authors:  Yvonne L Eaglehouse; Stephanie Shao; Wenyaw Chan; Derek Brown; Janna Manjelievskaia; Craig D Shriver; Kangmin Zhu
Journal:  J Cancer Surviv       Date:  2018-02-17       Impact factor: 4.442

5.  Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme.

Authors:  Ondrej Majek; Jan Danes; Miroslava Skovajsova; Helena Bartonkova; Lucie Buresova; Daniel Klimes; Petr Brabec; Pavel Kozeny; Ladislav Dusek
Journal:  BMC Public Health       Date:  2011-05-10       Impact factor: 3.295

6.  Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.

Authors:  Grace Hui-Min Wu; Yi-Ming Wang; Amy Ming-Fang Yen; Jau-Min Wong; Hsin-Chih Lai; Jane Warwick; Tony Hsiu-Hsi Chen
Journal:  BMC Cancer       Date:  2006-05-24       Impact factor: 4.430

7.  A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy.

Authors:  C-D Chen; M-F Yen; W-M Wang; J-M Wong; T H-H Chen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

8.  Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.

Authors:  Y-Y Wu; M-F Yen; C-P Yu; H-H Chen
Journal:  Br J Cancer       Date:  2013-05-14       Impact factor: 7.640

9.  Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.

Authors:  Justin Shows; Dongfeng Wu
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

10.  The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease.

Authors:  Y-C Lee; A M-F Yen; J J Tai; S-H Chang; J-T Lin; H-M Chiu; H-P Wang; M-S Wu; T H-H Chen
Journal:  Gut       Date:  2008-10-20       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.